A clinical trial used RMP-7, an agonist of bradykinin, to increase permeability of the blood-tumor barrier for entrance of carboplatin, a chemotherapeutic agent, into tumor sites for GBM therapy [18]. Here, KNG1 is linked to glioblastoma.